Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly versus every-3-weeks paclitaxel for anthracycline-pretreated metastatic breast cancer
NL-OMON29217Phase 3Active, not recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Jan 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in breast cancer (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Progression-free survival. Started Jan 2000; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON29217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29217.